BCMA CHO Recombinant Cell Line (High Expression)

Catalog #: 79500-H
Size: 2 vials
Species: Human
Genbank #: NM_001192
B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein encoded by the TNFRSF17 gene. TNFRSF17 is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. CART-BCMA is an autologous T cell product engineered by lentiviral transduction to express a fully human BCMA-specific CAR (chimeric antigen receptor). CAR T cells targeting BCMA have pre-clinical anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy breakthrough designation in Multiple Myeloma.
Recombinant clonal stable CHO cell line constitutively expressing full length human BCMA protein, also known as TNFRSF17, (Genbank #NM_001192). Surface expression of BCMA was confirmed by flow cytometry.
tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269
Supplied As:
Each vial contains ~ 2 x 106 cells in 1 ml of 10% DMSO in FBS
Host Cell line:
Mycoplasma Testing:
This cell line has been screened using the MycoAlertâ„¢ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.
Growth Media:

Thaw Medium 3 (BPS Bioscience, #60186): Ham’s F-12 medium (Hyclone #SH30526.01) supplemented with 10% FBS (Life technologies #26140-079), 1% Penicillin/Streptomycin (Hyclone #SV30010.01).

Growth Medium 3D (BPS Bioscience, #79539): Thaw Medium 3 (BPS Bioscience, #60186) plus 1 mg/ml G418 (Thermo Fisher, #11811031).

Instructions for use:
See data sheet for detailed culturing and assay protocol
Storage / Stability:
Immediately upon receipt, store vials in liquid nitrogen

1. Ghosh A, et al. CAR T cell therapy for multiple myeloma Leuk Lymphoma. 2017 Nov; 6:1-12.

2. Sanchez E, et al. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Rev Mol Diagn. 2018 Mar; 7:1-11.

3. Sohail A., et al. Emerging immune targets for the treatment of multiple myeloma. Immunotherapy. 2018 Feb 1; 10(4):265-282.

4. Sidaway P., et al. Anti-BCMA CAR T cells show promise in MM. Nat Rev Clin Oncol. 2016 Sep;13(9):530.

Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of BPS products to your laboratory. BPS does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact sales@bpsbioscience.com for details. Publications using this cell line should reference BPS Bioscience, Inc., San Diego.
Avoid freeze/thaw cycles
Scientific Category:
Product Type:
Cell line
Data shown is lot-specific. Contact us for specific information on other lots.

Quality Assurance

Product Datasheets